FORM 4

Check this box if no longer subject to

may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Section 16. Form 4 or Form 5 obligations

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box to indicate that a
	transaction was made pursuant to a
-	contract, instruction or written plan for the
	purchase or sale of equity securities of the
	issuer that is intended to satisfy the
	affirmative defense conditions of Rule
	10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person [*] CARUSO JAMES V			2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) C/O CELLECT	(First) AR BIOSCIENC	(Middle) CES, INC.	3. Date of Earliest Transaction (Month/Day/Year) 07/02/2025		Director Officer (give title below) Chief Executi	10% Owner Other (specify below) ve Officer				
100 CAMPUS I (Street) FLORHAM PARK	DRIVE	07932	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	 Individual or Joint/Group Filing (Check Ap X Form filed by One Reporting Pers Form filed by More than One Rep 					
(City)	(State)	(Zip) Table I - Non		ficially Ow	ned					

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct (D) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 7. Nature of Transaction Date Execution Date. Securities Indirect (Month/Day/Year) if any Code (Instr. Beneficially Owned or Indirect (I) Beneficial (Month/Dav/Year) 8) Following Reported (Instr. 4) Ownership Transaction(s) (Instr. 4) (A) or (Instr. 3 and 4) Code v Amount Price D)

Р

10,000

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year) r		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrants	\$5.25	07/02/2025		Р		10,000		07/02/2025	07/02/2030	Common Stock	10,000	\$0.01	10,000	D	

Explanation of Responses:

Common Stock

1. This number has been adjusted for the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025.

/s/ Christina Blakley, attorney-in-07/03/2025

fact for James V. Caruso ** Signature of Reporting Person Date

\$4.99

Α

11,638(1)

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

07/02/2025

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.